β-blockers reduce bone resorption marker in early postmenopausal women

2005 ◽  
Vol 32 (6) ◽  
pp. 738-745 ◽  
Author(s):  
Julie A. Pasco ◽  
Margaret J. Henry ◽  
Geoffrey C. Nicholson ◽  
Hans G. Schneider ◽  
Mark A. Kotowicz
Author(s):  
Sook Yee Lim ◽  
Yoke Mun Chan ◽  
Vasudevan Ramachandran ◽  
Zalilah Mohd Shariff ◽  
Yit Siew Chin ◽  
...  

Background: Evidence is growing that a high-acid diet might accelerate the rate of bone loss, and gene polymorphisms such as Interleukin 6 (IL6) -174G/C and -572G/C are related to bone deterioration. However, no study of the interaction between diet and IL6 polymorphisms has been conducted among Asians. Thus, the objective of this study was to determine whether IL6 gene polymorphisms modified the association between dietary acidity and the rate of bone resorption. Methods: This cross-sectional study recruited 203 postmenopausal women (age ranged from 51 to 85 years old) in community settings. The dietary intakes of the participants were assessed using a validated interviewer-administered semi-quantitative food frequency questionnaire (FFQ), while dietary acid load (DAL) was estimated using net endogenous acid production (NEAP). Agena® MassARRAY genotyping analysis and serum collagen type 1 cross-linked C-telopeptide (CTX1) were used to identify the IL6 genotype and as a bone resorption marker, respectively. The interactions between diet and single-nucleotide polymorphisms (SNPs) were assessed using linear regressions. Results: A total of 203 healthy postmenopausal women aged between 51 and 85 years participated in this study. The mean BMI of the participants was 24.3 kg/m2. In IL6 -174 G/C, all the participants carried the GG genotype, while the C allele was absent. Approximately 40% of the participants had a high dietary acid load. Dietary acid load (B = 0.15, p = 0.031) and the IL6 -572 CC genotype group (B = 0.14, p = 0.044) were positively associated with a higher bone resorption. However, there was no moderating effect of the IL6 genetic polymorphism on the relationship between and acid ash diet and bone resorption markers among the postmenopausal women (p = 0.79). Conclusion: High consumption of an acid ash diet and the IL6 -572 C allele seem to attribute to high bone resorption among postmenopausal women. However, our finding does not support the interaction effect of dietary acidity and IL6 (-174G/C and -572G/C) polymorphisms on the rate of bone resorption. Taken together, these results have given scientific research other candidate genes to focus on which may interact with DAL on bone resorption, to enhance planning for preventing or delaying the onset of osteoporosis among postmenopausal women.


2013 ◽  
Vol 98 (2) ◽  
pp. 571-580 ◽  
Author(s):  
Kim Brixen ◽  
Roland Chapurlat ◽  
Angela M. Cheung ◽  
Tony M. Keaveny ◽  
Thomas Fuerst ◽  
...  

Abstract Context: Odanacatib, a cathepsin K inhibitor, increases spine and hip areal bone mineral density (BMD) in postmenopausal women with low BMD and cortical thickness in ovariectomized monkeys. Objective: The objective of the study was to examine the impact of odanacatib on the trabecular and cortical bone compartments and estimated strength at the hip and spine. Design: This was a randomized, double-blind, 2-year trial. Setting: The study was conducted at a private or institutional practice. Participants: Participants included 214 postmenopausal women with low areal BMD. Intervention: The intervention included odanacatib 50 mg or placebo weekly. Main Outcome Measures: Changes in areal BMD by dual-energy x-ray absorptiometry (primary end point, 1 year areal BMD change at lumbar spine), bone turnover markers, volumetric BMD by quantitative computed tomography (QCT), and bone strength estimated by finite element analysis were measured. Results: Year 1 lumbar spine areal BMD percent change from baseline was 3.5% greater with odanacatib than placebo (P < .001). Bone-resorption marker C-telopeptide of type 1 collagen was significantly lower with odanacatib vs placebo at 6 months and 2 years (P < .001). Bone-formation marker procollagen I N-terminal peptide initially decreased with odanacatib but by 2 years did not differ from placebo. After 6 months, odanacatib-treated women had greater increases in trabecular volumetric BMD and estimated compressive strength at the spine and integral and trabecular volumetric BMD and estimated strength at the hip (P < .001). At the cortical envelope of the femoral neck, bone mineral content, thickness, volume, and cross-sectional area also increased from baseline with odanacatib vs placebo (P < .001 at 24 months). Adverse experiences were similar between groups. Conclusions: Over 2 years, odanacatib decreased bone resorption, maintained bone formation, increased areal and volumetric BMD, and increased estimated bone strength at both the hip and spine.


1998 ◽  
Vol 62 (1) ◽  
pp. 8-12 ◽  
Author(s):  
F. Scopacasa ◽  
M. Horowitz ◽  
J. M. Wishart ◽  
A. G. Need ◽  
H. A. Morris ◽  
...  

2003 ◽  
Vol 111 (8) ◽  
pp. 1221-1230 ◽  
Author(s):  
Guitty Eghbali-Fatourechi ◽  
Sundeep Khosla ◽  
Arunik Sanyal ◽  
William J. Boyle ◽  
David L. Lacey ◽  
...  

2007 ◽  
Vol 22 (5) ◽  
pp. 724-729 ◽  
Author(s):  
Natthinee Charatcharoenwitthaya ◽  
Sundeep Khosla ◽  
Elizabeth J Atkinson ◽  
Louise K McCready ◽  
B Lawrence Riggs

Trials ◽  
2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Maryam Abshirini ◽  
Jane Coad ◽  
Frances M. Wolber ◽  
Pamela von Hurst ◽  
Matthew R. Miller ◽  
...  

Abstract Background New Zealand Greenshell™ mussels (GSM; Perna canaliculus) have recently been shown to decrease cartilage degradation in a rat model of induced metabolic osteoarthritis (MetOA). However, this effect has not been investigated in human subjects. This study aims to determine the effect of GSM powder on biomarkers of cartilage metabolism, bone resorption, and inflammation in New Zealand healthy overweight/obese postmenopausal women who are at early stage or at high risk of OA. Method Fifty overweight or obese (BMI 25–35 kg/m2) postmenopausal women (aged 55–75 years) will be recruited by advertisement. Participants will be randomized based on a double-blind randomization schedule and stratified randomization based on BMI and age distribution. The participant will be assigned with a 1:1 allocation ratio to receive 3 g/d whole meat GSM powder or placebo (sunflower seed protein) for 12 weeks. Data on socio-demographics, physical activity, and dietary intake will be collected for each subject. Cartilage turnover biomarkers [(C-telopeptide of type II collagen (CTX-II), C-propeptide of type II procollagen (CPII), Cartilage oligomeric matrix protein (COMP)], and bone resorption marker (CTX-I) will be measured in blood and urine samples. Inflammatory status (hs-CRP and cytokine panel) will be assessed and iron status will be measured. Body composition including fat mass (FM), lean mass (LM), and fat percentage will be measured using dual-energy X-ray absorptiometry (DXA). Joint pain and knee function will be assessed using a 100-mm visual analog scale (VAS) and the Knee Injury and Osteoarthritis Outcome Score (KOOS) questionnaire, respectively. Discussion This trial will be the first to explore the effects of whole meat GSM powder on cartilage turnover, bone resorption, and inflammation biomarkers in overweight/obese postmenopausal women. The results from this trial will provide evidence on the efficacy of GSM in the prevention of OA. Trial registration Australian New Zealand Clinical Trials Registry (ANZCTR) ACTRN12620000413921p. Registration on 27 March 2020.


2020 ◽  
Vol 32 (4) ◽  
pp. 705-712
Author(s):  
G. Gayathri ◽  
AJ Hemamalini

Background: Indigenous plant based dietary supplement that is accessible and safer may help to combat the more proclaimed calcium deficiency among Indian population and improve bone strength. Aim & Objective: To formulate an indigenous calcium rich food supplement and study its impact on markers of bone resorption and formation. Settings and Design: Sixty subjects (80% power, α = 0.05) including 30 perimenopausal and postmenopausal women each were randomly assigned to control and experimental groups. Methods and Material: Experimental postmenopausal and perimenopausal women received 1200mg and 800mg per day of calcium respectively from a plant based supplement comprising Sesamum indicum, Eleusine coracana, Glycine max Vigna mungo and Sesbania grandiflora as a midmorning and evening snack. Measures like serum calcium, betacrosslaps (bone resorption marker), total P1NP (bone formation marker) were assessed at baseline, 3rd and 6th month. Results: Fifty-seven subjects were analysed with no adverse events were reported. Results showed that after supplementation betacrosslaps reduced from 0.32±0.130 ng/ml to 0.25±0.130 ng/ml and 1.11±0.290 ng/ml to 0.42±0.263 ng/ml in perimenopausal and postmenopausal subjects significant at (P=0.008) and (P=0.012) respectively. Conclusions: Adequate dietary calcium intake using locally available foods is recommended as a strategic option in reducing risk of osteoporosis.


Sign in / Sign up

Export Citation Format

Share Document